​

ALX Oncology (ALXO) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

ALXO Stock Forecast

ALX Oncology (ALXO) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $4.00, with a high of $4.00 and a low of $4.00. This represents a 86.05% increase from the last price of $2.15.

- $4 $8 $12 $16 $20 High: $4 Avg: $4 Low: $4 Last Closed Price: $2.15

ALXO Stock Rating

ALX Oncology stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (85.71%), 1 Hold (14.29%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 1 6 Strong Sell Sell Hold Buy Strong Buy

ALXO Price Target Upside V Benchmarks

TypeNameUpside
StockALX Oncology86.05%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-11
Avg Price Target-$4.00$4.00
Last Closing Price$2.15$2.15$2.15
Upside/Downside-86.05%86.05%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26131--5
Feb, 26131--5
Jan, 26131--5
Dec, 25131--5
Nov, 25221--5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 05, 2026Piper Sandler$4.00$2.0199.00%86.05%
Mar 07, 2025Stifel Nicolaus$1.50$1.0641.51%-30.23%
Jun 10, 2024Colin BristowUBS$25.00$8.83183.13%1062.79%
Jun 03, 2024Christopher RaymondRaymond James$21.00$9.10130.77%876.74%
Apr 10, 2024Bradley CaninoStifel Nicolaus$14.00$11.8518.14%551.16%
Aug 09, 2022Credit Suisse$38.00$11.77222.85%1667.44%
Jun 13, 2022Bradley CaninoStifel Nicolaus$16.00$6.79135.64%644.19%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 05, 2026Piper SandlerOverweightOverweighthold
Mar 06, 2025Piper SandlerOverweightOverweighthold
Dec 19, 2024JefferiesBuyHolddowngrade
Jun 10, 2024UBSBuyBuyhold
Jun 03, 2024Piper SandlerOverweightOverweighthold
May 10, 2024H.C. WainwrightBuyBuyhold
Dec 08, 2023JefferiesBuyupgrade
Aug 09, 2022Credit SuisseOutperformOutperformhold
May 19, 2022Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.07$-3.74$-2.58$-1.90---
Avg Forecast$-1.93$-3.61$-2.76$-2.50$-2.09$-2.02$-1.19
High Forecast$-1.93$-3.44$-2.62$-2.21$-1.29$-1.62$-1.19
Low Forecast$-1.93$-3.87$-2.97$-2.79$-2.80$-2.42$-1.19
Surprise %7.25%3.60%-6.52%-24.00%---

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-------
Avg Forecast$168.86K-$1.16M$625.00K$4.60M$43.89M$146.04M
High Forecast$168.86K-$1.16M$625.00K$4.60M$43.89M$146.04M
Low Forecast$168.86K-$1.16M$625.00K$4.60M$43.89M$146.04M
Surprise %-------

Net Income Forecast

$-200M $-170M $-140M $-110M $-80M $-50M Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-83.46M$-160.81M$-134.85M$-101.69M---
Avg Forecast$-83.14M$-160.81M$-119.98M$-107.64M$-87.86M$-86.84M$-51.26M
High Forecast$-83.14M$-147.74M$-112.46M$-95.16M$-55.32M$-69.47M$-51.26M
Low Forecast$-83.14M$-166.21M$-127.49M$-120.13M$-120.40M$-104.20M$-51.26M
Surprise %0.39%-12.40%-5.52%---

ALXO Forecast FAQ

Is ALX Oncology stock a buy?

ALX Oncology stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that ALX Oncology is a favorable investment for most analysts.

What is ALX Oncology's price target?

ALX Oncology's price target, set by 7 Wall Street analysts, averages $4 over the next 12 months. The price target range spans from $4 at the low end to $4 at the high end, suggesting a potential 86.05% change from the previous closing price of $2.15.

How does ALX Oncology stock forecast compare to its benchmarks?

ALX Oncology's stock forecast shows a 86.05% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for ALX Oncology over the past three months?

  • March 2026: 20.00% Strong Buy, 60.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 20.00% Strong Buy, 60.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 20.00% Strong Buy, 60.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.

What is ALX Oncology’s EPS forecast?

ALX Oncology's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.09, marking a 10.00% increase from the reported $-1.9 in 2025. Estimates for the following years are $-2.02 in 2027, and $-1.19 in 2028.

What is ALX Oncology’s revenue forecast?

ALX Oncology's average annual revenue forecast for its fiscal year ending in December 2026 is $4.6M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $43.89M, and $146.04M for 2028.

What is ALX Oncology’s net income forecast?

ALX Oncology's net income forecast for the fiscal year ending in December 2026 stands at $-87.86M, representing a -13.60% decrease from the reported $-102M in 2025. Projections indicate $-86.836M in 2027, and $-51.263M in 2028.